Evidence map›Paper›PMID 30386685›Full record

ArticleCurrent genetic medicine reports2018

Mitochondrial Genomics: A complex field now coming of age.

Elizabeth M McCormick, Colleen C Muraresku, Marni J Falk

Open access · greenAbstract read
In one paragraph

Article in Current genetic medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 52 citations in OpenAlex.

  1. Trial
  2. Advances in Management of Mitochondrial Myopathies.International journal of molecular sciences · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Nuclear-Encoded lncRNAMolecular therapy. Nucleic acids · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Elizabeth M McCormickDivision of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Colleen C MurareskuDivision of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Marni J FalkDivision of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Children's Hospital of Philadelphia · USUniversity of Pennsylvania · US

Funding

Pharmacologic Treatment of Mitochondrial Complex I Dysfunction in C. ElegansR01GM120762 · NIGMS · CHILDREN'S HOSP OF PHILADELPHIA · PI FALK, MARNI J · 2016 to 2019
$2.4M
Primary Mitochondrial Disease Expert Curation PanelU24HD093483 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI FALK, MARNI J, GAI, XIAOWU · 2017 to 2023
$2.2M
NICHD NIH HHS U24 HD093483NIGMS NIH HHS R01 GM120762
6 · The paper itself

Abstract

purpose of reviewThe groundwork for mitochondrial medicine was laid 30 years ago with identification of the first disease-causing mitochondrial DNA (mtDNA) mutations in 1988. Three decades later, mutations in nearly 300 genes involving every possible mode of inheritance within both nuclear and mitochondrial genomes are now recognized to collectively comprise the largest class of inherited metabolic disease affecting at least 1 in 4,300 individuals across all ages. Significant progress has been made in recent years to improve understanding of mitochondrial biology and disease pathophysiology. RECENT

findingsMarkedly improved understanding of the highly diverse molecular etiologies of multi-systemic phenotypes in primary mitochondrial disease has resulted from massively parallel genomic sequencing technologies and improved bioinformatic resources that enable identification in individual patients of their disease's precise genetic etiology. Key informatics resources of particular utility to the mitochondrial disease genomics community have been developed, including: (1) Mitocarta 2.0 repository of 1200+ verified mitochondria-localized proteins, (2) MITOMAP Web resource of curated mtDNA genome variants, and (3) Mitochondrial Disease Sequence Data Resource (MSeqDR) that centralizes Web curation and annotation of mitochondrial disease genes and variants in both genomes, ontology-defined phenotypes, and access to many analytic tools to support genomic data mining and interpretation. Gene and mutation-based disease categorization has proven particularly useful to identify the full clinical spectrum of disease that may affect a given individual. SUMMARY: Extensive genomic advances, both in technologic platforms and bioinformatics resources, have facilitated dramatic improvement in the accurate recognition and understanding of primary mitochondrial disease.

Indexed as

databasegenomicsmitochondrial diseasepathophysiology

Identifiers

PMID30386685
PMCPMC6205240
OpenAlexW2801469730

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.